Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of July 2018. The report details the outcomes of the Company's 2018 Annual General Meeting of Shareholders held on July 24, 2018, in Rehovot, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses on corporate governance actions rather than financial performance data.
Material Changes and Corporate Actions
Shareholders approved the following proposals at the Annual General Meeting:
- Board Re-election: Re-election of the current Board of Directors (Martin S. Gerstel, Sarit Firon, Ziv Kop, Dr. Adina Makover, and Leon Y. Recanati) for a one-year term.
- Compensation Policy: Approval of an amendment to the compensation policy for directors and other office holders.
- CEO Bonus Plan: Approval of objectives and target amounts for a 2019 cash bonus for the President & CEO, contingent on 2018 performance.
- Stock Option Grant: Approval of a grant of options to purchase 225,000 ordinary shares to President & CEO Ofer Haviv at an exercise price of NIS 18.71 (approximately US$5.22).
- Auditor Ratification: Re-appointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as the independent registered public accounting firm for the year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, outlook statements, or a discussion of risks and contingencies. It references a proxy statement filed on June 14, 2018, for more detailed descriptions of the proposals.
Key Facts for Investor Verification
- Verify the specific terms of the amended director compensation policy.
- Review the detailed performance objectives for the CEO's 2019 cash bonus in the June 14, 2018 proxy statement.
- Confirm the dilution impact of the 225,000 share option grant to the CEO.
- Check the Company's Form 20-F for the most recent audited financial statements, as this 6-K contains no financial data.